{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:19:20Z","timestamp":1783070360281,"version":"3.54.6"},"reference-count":18,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>We appreciate the comment [...]<\/jats:p>","DOI":"10.3390\/toxins18070292","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:59:47Z","timestamp":1783065587000},"page":"292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to St\u00e5hl et al. Comment on \u201cHonndorf et al. Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA. Toxins 2026, 18, 142\u201d"],"prefix":"10.3390","volume":"18","author":[{"given":"Stefanie","family":"Honndorf","sequence":"first","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"K\u00fchbach","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Eisele","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Shokurova","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Buch","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Jatzke","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold Victor","family":"Taylor","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fink","sequence":"additional","affiliation":[{"name":"Merz Therapeutics GmbH, Neurotoxin & Biotechnology Development, Eckenheimer Landstr. 100, 60318 Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"St\u00e5hl, U., Hamnevik, E., Liljegren Sundberg, \u00c5., Persson, C., and Prygova, I. (2026). Comment on Honndorf et al. Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA. Toxins 2026, 18, 142. Toxins, 18.","DOI":"10.3390\/toxins18030142"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108671","DOI":"10.1016\/j.toxicon.2025.108764","article-title":"Cellular Responses to Botulinum Neurotoxin A Formulations: Implications with HSA and Polysorbates on Skin-Derived Cell Types","volume":"271","author":"Hartmann","year":"2026","journal-title":"Toxicon"},{"key":"ref_3","unstructured":"Jelinek, A. (2001). In-Vitro-Toxizit\u00e4t Grenzfl\u00e4chenaktiver Substanzen: Wirkung auf Zellmembran, Mitochondriale Funktion und Apoptose. [Doctoral Dissertation, Luther-Universitaet Halle-Wittenberg]. Available online: https:\/\/opendata.uni-halle.de\/\/handle\/1981185920\/9775."},{"key":"ref_4","unstructured":"EMA (2026, June 08). Information for the Package Leaflet Regarding Polysorbates Used as Excipients in Medicinal Products for Human Use, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0304-4157(75)90016-7","article-title":"Solubilization of membranes by detergents","volume":"415","author":"Helenius","year":"1975","journal-title":"Biochim Biophys. Acta"},{"key":"ref_6","unstructured":"FDA (2026, June 08). Inactive Ingredients Database, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/inactive-ingredients-database-download."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/jps.21190","article-title":"Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways","volume":"97","author":"Kerwin","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.xphs.2022.10.012","article-title":"Extensive Characterization of Polysorbate 80 Oxidative Degradation Under Stainless Steel Conditions","volume":"112","author":"Zheng","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_9","first-page":"1052","article-title":"IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines","volume":"20","author":"Kerscher","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/asj\/sjae131","article-title":"Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines","volume":"44","author":"Shridharani","year":"2024","journal-title":"Aesthetic Surg. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12984-026-01895-x","article-title":"Electrical or magnetic nerve stimulation enhance the BoNT\/A-mediated muscle paralysis","volume":"23","author":"Honndorf","year":"2026","journal-title":"J. Neuroeng. Rehabil."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14746","DOI":"10.1038\/s41598-017-14997-3","article-title":"Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures","volume":"7","author":"Pingel","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcpt.12351","article-title":"Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats","volume":"116","author":"Torii","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jns.2014.06.028","article-title":"Intramuscular distribution of botulinum toxin\u2014Visualized by MRI","volume":"344","author":"Elwischger","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ultrasmedbio.2020.06.022","article-title":"Ultrasound Imaging of Injections in Masseter Muscle without Contrast Agent Using Strain Elastography and a Novel B-Mode Spatiotemporal Filter","volume":"46","author":"Sanabria","year":"2020","journal-title":"Ultrasound Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2133.2001.03961.x","article-title":"Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: Measured by sudometry","volume":"144","author":"Braune","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hed.2880120504","article-title":"Botulinum A toxin for the treatment of spasmodic torticollis: Dysphagia and regional toxin spread","volume":"12","author":"Borodic","year":"1990","journal-title":"Head Neck"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/DSS.0000000000003171","article-title":"A Cadaveric Study of Dye Spreading: Determining the Ideal Injection Pattern for Masseter Hypertrophy","volume":"47","author":"Sermswan","year":"2021","journal-title":"Dermatol. Surg."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/7\/292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:43:44Z","timestamp":1783068224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/7\/292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["toxins18070292"],"URL":"https:\/\/doi.org\/10.3390\/toxins18070292","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}